[Association of polymorphism in alpha-adducin gene with antihypertensive effect of Hydrochlorothiazide].
OBJECTIVE
To explore the association between G614T single nuclear polymorphism (SNP) of the alpha-adducin gene and the antihypertensive effect of hydrochlorothiazide (HCTZ) in essential hypertensive (EH) patients.


METHODS
Eight hundred twenty nine EH patients were given 12.5 mg HCTZ/d for six weeks. Alpha-adducin gene G614T SNP in the tenth exon was determined by PCR-RFLP in 754 patients with complete records. All the patients were grouped according to TT, GT and GG genotypes.


RESULTS
After 6 weeks of HCTZ treatment, the decreases in DBP and MAP of patients carrying 614T allele of alpha-adducin were significantly greater than that of those carrying GG homozygotes (P < 0.05). The decreases in SBP and MAP were significantly greater in patients with the TT genotype as compared with GT or GG genotype (P < 0.05). The effective rate of BP fall by HCTZ was higher in patients with TT genotype than those with GT or GG genotype (P < 0.05). Multivariate stepwise regression analysis showed that the TT genotype and the baseline SBP were the two major predictors affecting the decrease in SBP.


CONCLUSIONS
The present study suggests that the alpha-adducin G614T polymorphism is associated with the antihypertensive effect of HCTZ, which is more effective in patients with TT genotype.
Wu
Shou-ling
SL
Affiliated Kailuan Hosptial of North Coal Medical College, Tangshan 063000, China. ldq661126@sina.com.cn
Li
Dong-qing
DQ
Li
Hong-fen
HF
Yu
Qing
Q
Li
Yun
Y
Zhao
Hai-yan
HY
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D002148:Calmodulin-Binding Proteins / Q000235:genetics*; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D016037:Single-Blind Method; D016896:Treatment Outcome; D000099291:Adducins
D000959:Antihypertensive Agents; D002148:Calmodulin-Binding Proteins; D006852:Hydrochlorothiazide; D000099291:Adducins